Cervical spondylotic amyotrophy

Jiang, Sheng‐Dan; Jiang, Lei‐Sheng; Dai, Li-Yang

doi:10.1007/s00586-010-1544-1

Cited by 48 publications

(51 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding can be attributes to the AHs located in the terminal territory of the sulcal (central) arteries, which are considered the most vulnerable to the effects of circulatory insufficiency 1. Wada et al 20.…”

Section: Discussionmentioning

confidence: 99%

“…Some researchers attribute the syndrome to the selective intradural compression of the ventral motor roots by posterolateral osteophytes 1. Others attribute it to a circulatory insufficiency in the territories of the spinal central arteries, as well as to selective damage to the AHs 1. Fujiwara et al 7.…”

Section: Discussionmentioning

confidence: 99%

“…Meanwhile, several researchers demonstrated that CSA may be characterized by multi segmental damage resulting from the loss of AH cells, which is possibly caused by dynamic cord compression through circulatory insufficiency 79121415. Given that the primary mechanism of compression is more ischemic than compressive, we can assume that minimal spondylotic changes in regions adjacent to the anterior spinal or feeder arteries can result in segmental ischemic events in the AHs 115. In our work, we also demonstrated that the most commonly affected levels were C4-C5 and C5-C6 for proximal and distal type CSA, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…CSA is characterized by severe muscle atrophy in the upper extremities, with or without significant sensory disturbance and lower extremity symptoms. Reports suggest that <7% of patients with cervical spondylotic myelopathy presented with minimal sensation loss 12. CSA has always been described as unilateral but can occasionally present as bilateral disease 3…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of characteristics and surgical outcomes in cervical spondylotic amyotrophy

Wang

Jiang

et al. 2014

IJOO

View full text Add to dashboard Cite

Background:Cervical spondylotic amyotrophy (CSA) is a rare clinical syndrome resulting from cervical spondylosis. Surgical treatment includes anterior cervical decompression and fusion (ACDF), and laminoplasty with or without foraminotomy. Some studies indicate that ACDF is an effective method for treating CSA because anterior decompression with or without medial foraminotomy can completely eliminate anterior and/or anterolateral lesions. We retrospectively evaluated outcome of surgical outcome by anterior cervical decompression and fusion (ACDF).Materials and Methods:28 CSA patients, among whom 12 had proximal type CSA and 16 had distal type CSA, treated by ACDF, were evaluated clinicoradiologically. The improvement in atrophic muscle power was assessed by manual muscle testing (MMT) and the recovery rate of the patients was determined on the basis of the Japanese Orthopedic Association (JOA) scores. Patient satisfaction was also examined.Results:The percentage of patients, who gained 1 or more grades of muscle power improvement, as determined by MMT, was 91.7% for those with proximal type CSA and 37.5% for those with distal type CSA (P < 0.01). The JOA score-based recovery rates of patients with proximal type and distal type CSA were 60.8% and 41.8%, respectively (P < 0.05). Patient satisfaction was 8.2 for those with proximal type CSA and 6.9 for those with distal type CSA (P < 0.01). A correlation was observed among the levels of improvement in muscle power, JOA score based recovery rate, patient satisfaction and course of disease (P < 0.05).Conclusion:ACDF can effectively improve the clinical function of patients with CSA and result in good patient satisfaction despite the surgical outcomes for distal type CSA being inferior to those for proximal type CSA. Course of disease is the fundamental factor that affects the surgical outcomes for CSA. We recommend that patients with CSA undergo surgical intervention as early as possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of characteristics and surgical outcomes in cervical spondylotic amyotrophy

Wang

Jiang

et al. 2014

IJOO

View full text Add to dashboard Cite

show abstract

“…also reported that the distal type showed a greater number of involved vertebrae causing cord compression and a poorer outcome than the proximal type. By literatures review, we can find two possible reasons to interpret the distinct surgical outcomes919. One possible reason is the longer distance from the cervical spinal cord or nerve root to the atrophic muscles in distal type than in proximal type.…”

Section: Discussionmentioning

confidence: 99%

Predisposing factors for poor outcome of surgery for cervical spondylotic amyotrophy: a multivariate analysis

Zhang

Cui

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The purpose of this study was to characterize risk factors for poor surgical outcome in patients with cervical spondylotic amyotrophy (CSA). We retrospectively reviewed 88 cases of CSA surgery and investigated age, sex, duration of symptoms, atrophy type, preoperative muscle power, signal changes on MRI, anterior horn (AH) or ventral nerve root (VNR) compression, compression levels, surgical approach and postoperative recovery. Fifty (56.8%) patients had good surgical outcome. Logistic regression, with poor outcome as dependent variable, showed independent risks associated with duration of symptoms (OR; 1 for symptom duration less than 3 months versus 3.961 [95% CI; 1.203–13.039, p = 0.024] for symptom duration of 3–6 months versus 18.724 [95% CI; 3.967–88.367, p < 0.001] for symptom duration greater than 6 months), compression type (OR; 1 for VNR versus 4.931 [95% CI; 1.457–16.685, p = 0.010] for AH versus 5.538 [95% CI; 1.170–26.218, p = 0.031] for VNR + AH), and atrophy type (OR; 1 for proximal type versus 6.456 [95% CI; 1.938–21.508, p = 0.002] for distal type). These findings suggest that a long duration of symptoms, AH or both AH and VNR compression, and distal type are risk factors for poor surgical outcome in patients with CSA.

show abstract

eEF‐2K knockdown synergizes with STS treatment to inhibit cell proliferation, migration, and invasion via the TG2/ERK pathway in A549 cells

Wang

Xiang

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Emerging research has suggested the anticancer potential of tanshinone IIA, the bioactive ingredient isolated from the traditional Chinese herb Salvia miltiorrhiza. However, the molecular mechanism of sodium tanshinone IIA sulfonate (STS) antilung cancer effect is not very clear. In this study, our purpose is to investigate the roles of STS and elongation factor-2 kinase (eEF-2K) in regulating the proliferation, migration, and invasion of A549 cells and explore the implicated pathways. We found that STS suppressed A549 cell survival and proliferation in a time-and xdose-dependent manner. Knockdown of eEF-2K and treatment with STS synergistically exerted antiproliferative, -migratory, and -invasive effects on A549 cells. These effects were caused by attenuation of the extracellular signal-regulated kinase (ERK) pathway via inhibition of tissue transglutaminase (TG2). In summary, the inhibition of eEF-2K synergizes with STS treatment, exerting anticancer effects on lung adenocarcinoma cells through the TG2/ERK signaling pathway, which provides a potential therapeutic target for treating lung adenocarcinoma.

show abstract

Cervical spondylotic amyotrophy

Cited by 48 publications

References 44 publications

Evaluation of characteristics and surgical outcomes in cervical spondylotic amyotrophy

Evaluation of characteristics and surgical outcomes in cervical spondylotic amyotrophy

Predisposing factors for poor outcome of surgery for cervical spondylotic amyotrophy: a multivariate analysis

eEF‐2K knockdown synergizes with STS treatment to inhibit cell proliferation, migration, and invasion via the TG2/ERK pathway in A549 cells

Contact Info

Product

Resources

About